Maryam Tehranipour | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Maryam Tehranipour | Pharmacology | Best Researcher Award

Animal Physiology | Islamic Azad University | Iran

Dr. Maryam Tehranipour is an accomplished Associate Professor in the Department of Biology at the Islamic Azad University, Mashhad, Iran, recognized for her distinguished contributions to the fields of diabetes, metabolic disorders, neurobiology, oxidative stress, and cancer biology. Holding a Ph.D. in Animal Physiology, she has built a dynamic academic and research career integrating cellular physiology, pharmacology, and molecular mechanisms of disease. Her extensive publication record spans a broad spectrum of biomedical investigations, including neuroprotective strategies, natural product pharmacology, nanomedicine, and experimental models of diabetes and neurodegeneration. Dr. Tehranipour’s pioneering studies have elucidated the roles of oxidative damage, angiogenesis, and neuronal regeneration in disease progression and therapeutic recovery, particularly highlighting the potential of bioactive compounds and nanocarrier systems in drug design and targeted therapy. Her collaborative work has advanced understanding of diabetic complications, nerve injury repair, and cancer cell modulation through natural and synthetic agents. Beyond her prolific research output, she has played a significant role in mentoring undergraduate, graduate, and doctoral students, fostering scientific rigor and innovation in physiological research. Her scholarly influence is reflected through her indexed publications, contributions to interdisciplinary research networks, and global collaborations that link physiology, biochemistry, and nanotechnology for translational health impact. Dr. Tehranipour’s scientific endeavors emphasize the integration of experimental biology with clinical relevance, aiming to bridge laboratory discoveries with therapeutic applications. Through her ongoing research, she continues to contribute meaningfully to global biomedical science, particularly in developing sustainable and biologically safe therapeutic interventions addressing chronic and degenerative diseases that pose major public health challenges. She has 238 citations from 53 documents with an h-index of 9.

Profile: Scopus 

Featured Publications

1. The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway. (2025). Scientific Reports. Open access.

2. The effects of N-butanol and ethyl acetate fractions of Ferula asafoetida hydroalcoholic extract on the expression of VEGF and FGF genes in the chorioallantoic membrane of chick embryos. (2025). Journal of Veterinary Research.Open access.

3. Bimetallic-based colorimetric aptasensor for the quantitative analysis of ampicillin using catalytic activity of ZrFe metal–organic framework and terminal deoxynucleotidyl transferase-assisted signal amplification. (2025). Bionanoscience. Open access.

4. The effect of Ziziphora clinopodioides hydroalcoholic extract on the neuronal density and histopathology of the hippocampal area CA2 in streptozotocin-induced Alzheimer’s model in male rats. (2025). Journal of Chemical Health Risks. Open access.

5. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. (2025). Journal of Molecular Liquids. Open access.

Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.